AIDS pricing lobbyists secure Gilead CEO bonus vote
This article was originally published in Scrip
Executive Summary
Gilead Sciences' shareholders will vote on whether chairman and CEO John Martin's bonus package should be linked to patients' access to its medicines, after the company failed to block the president of the non-profit Aids Healthcare Foundation (AHF), an outspoken critic of Gilead's drug pricing policies, from submitting the proposal for the annual stockholders' meeting.